Publication date: 21/03/2019
Today, the members of the NEURONET project announced the start of a new collaborative pan-European coordination and support initiative for the Innovative Medicines Initiative (IMI) projects of the Neurodegenerative Disorders (ND) portfolio. CMAST - a leading consultancy and project management company in life sciences – is also involved in this project, in support of Janssen Pharmaceutica.
NEURONET will set up a platform that will enable collaboration across the IMI ND portfolio by assisting in identifying gaps, multiplying the portfolio’s impact, and enhancing its visibility with related initiatives in Europe and worldwide.
NEURONET consists of a small number of active partners in a variety of IMI ND projects and related initiatives. Its partners are specialists in complex/project management, data sharing & re-use, drug development, patient engagement, communication, sustainability and regulatory/HTA interactions.
This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 821513. The JU receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA and Parkinson’s UK.
CMAST is a leading consultancy and project management company in life sciences.
With a team of more than 90 industry experts, CMAST provides support to pharma and life sciences companies, universities and research institutes.
The company offers consultancy, project management and tangible business solutions in the following areas:
CMAST is headquartered in Temse (Belgium) and has branches in Germany, Poland and the US. Since 2018, CMAST is working together closely with XPE Pharma & Science to connect life sciences businesses and talent in a fast-changing world. CMAST and XPE Pharma & Science are both part of the Modis Group, which gives the companies a global reach. More info on https://www.c-mast.com